Pharma merger
As the opioid crisis grabs the headlines, the search for safe treatments continues
Indivior’s Gilles Picard charts a path to greater patient access and new therapies
Indivior push to diversify boosted by schizophrenia drug approval
Perseris will face competition from Lundbeck/Otsuka’s Abilify Maintena and J&J’s Invega Sustenna
GSK joins Reckitt in passing on Pfizer’s consumer health unit
The healthcare business doesn’t meet GSK’s criteria for returns, says Walmsley
FDA panel backs Indivior’s drug to fight opioid addiction
The former RB pharma unit hopes for sales in the $1bn region
Indivior slumps as patent dispute rises US generic spectre
The RB spin out will appeal against the ruling
Reckitt to spin-off pharma unit as Indivior
Demerged business will focus on opioid dependence product Suboxone
Reckitt Benckiser confirms pharma spin-off plans
Will separate prescription and consumer health businesses